# Adamas Pharmaceuticals

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/adamas-pharmaceuticals

- Industry: Pharmaceuticals
- Headquarters: Emeryville, US
- Total disclosed funding: $67M
- Latest round: Series D (Oct 1, 2009)
- Investors on record: 4

## About

Founded in 2002 and based in California, US, Adamas Pharmaceuticals, Inc. develops small-molecule-advantaged therapeutics to treat neurological and infectious diseases. In October 2021, Supernus Pharmaceuticals, Inc., a portfolio company of Abingworth, New Enterprise Associates, and OrbiMed Advisors, agreed to acquire Adamas Pharmaceuticals, Inc. from Aeris Capital, DAG Ventures, Mohr Davidow Ventures, and Northgate Capital for approximately USD 450 million. As of October 2021, the company is led by CEO Neil McFarlane.
 
Adamas Pharmaceuticals, Inc. offers GOCOVRI, an extended-release capsule medication for treating levodopa-induced dyskinesia in Parkinson's patients. OSMOLEX ER, another extended-release medication containing amantadine, is used for treating Parkinson's disease and drug-induced side effects. The company also offers Namzaric, a medication combining memantine and donepezil for Alzheimer's disease.

## Funding rounds

- Series D, Oct 1, 2009, $40M — Mohr Davidow Ventures, DAG Ventures, Northgate Capital, Aeris Capital
- Series C, Jun 30, 2006, $6.3M — Mohr Davidow Ventures
- Series B, May 1, 2005, $21M — Mohr Davidow Ventures

## Investors

- Mohr Davidow Ventures (https://capitalatlas.ai/funds/mohr-davidow-ventures) — Series B, Series C, Series D
- DAG Ventures (https://capitalatlas.ai/funds/dag-ventures) — Series D
- Northgate Capital (https://capitalatlas.ai/funds/northgate-capital) — Series D
- Aeris Capital — Series D